[DOI] [PMC free article] [PubMed] [Google Scholar] 191.Khunti K, Chatterjee S, Gerstein HC, Zoungas S, Davies MJ
PubMed , Fenton, Anna
With PF3944 as an anchor of Pfizers obesity pipeline, we are positioned to address critical gaps in obesity care and meet the diverse needs of patients. Following its recent acquisition of Metsera and exclusive global collaboration and license agreement with YaoPharma, Pfizer now has a diverse pipeline of clinical stage injectable and oral obesity candidates targeting GLP-1 receptor as well as glucose-dependent insulinotropic polypeptide receptor (GIPR) agonists and antagonists, and amylin analogs
I recently made the decision to not continue serving on the board of Weight Watchers and I made that decision because I wanted no perceived conflict of interest for this special, Winfrey said
Together, we can develop a personalized plan to help you reach your ideal weight, control your blood sugar, and reduce your risk of developing or worsening type 2 diabetes